Opening: Real Consultation Scenario
Clinic Scenario A 28-year-old thalassemia carrier sits in the consultation room, her eyes filled with cautious hope and expectation: "Doctor, I have a genetic disease. Can IVF in China screen it out? Or do I have to go abroad?" This is one of the most common questions asked by families with genetic diseases when they visit a reproductive center.
Can Genetic Diseases Be Blocked Through IVF Technology in China?
Yes. Currently, China has multiple qualified reproductive medicine centers offering Third-Generation IVF Technology (PGT, Preimplantation Genetic Testing), which is specifically used for genetic testing of embryos. It screens embryos that do not carry pathogenic genes or have normal chromosomes for transfer, thereby preventing the transmission of genetic diseases to offspring.
PGT technology is divided into three types:
- PGT-M (Monogenic Disease Testing) — For diseases with clear pathogenic gene mutations such as thalassemia, spinal muscular atrophy (SMA), hereditary deafness, hemophilia, and cystic fibrosis.
- PGT-SR (Structural Rearrangement Testing) — For chromosomal structural abnormalities such as balanced translocations, Robertsonian translocations, and inversions.
- PGT-A (Aneuploidy Screening) — For chromosomal numerical abnormalities, such as Down syndrome, and also applicable to advanced maternal age and recurrent miscarriage patients.
It is important to clarify: The prerequisite for PGT technology is that the pathogenic gene or chromosomal abnormality has been clearly diagnosed and a feasible testing protocol is available. Not all genetic diseases can be completely blocked by PGT, as will be explained further below.
Specific Process of IVF for Genetic Diseases
From genetic counseling to embryo transfer, the entire process typically takes 3 to 6 months and includes the following key steps:
Step 1: Genetic Counseling and Family Verification
Both partners need to visit a genetic counseling clinic or reproductive genetics clinic. The doctor will assess the inheritance pattern of the genetic disease (autosomal dominant/recessive, X-linked, mitochondrial inheritance, etc.) and confirm whether PGT is indicated. If there is a proband (affected family member) in the family, their DNA sample is needed for probe design.
Step 2: Genetic Testing and Probe Design
After identifying the pathogenic mutation, the laboratory needs to customize genetic testing probes for the family. This step takes 1 to 3 months and is the most critical part of the PGT-M process. Probe design requires blood samples from the proband or both partners. Some complex mutations (such as de novo mutations, deletions/duplications) may require longer verification time.
Step 3: Entering the IVF Cycle
After probe verification is successful, the woman begins ovarian stimulation treatment (about 10-14 days). Follicle development is monitored via ultrasound and hormone levels, and egg retrieval is performed when the timing is right. On the same day, the man provides a sperm sample for in vitro fertilization (conventional IVF or ICSI).
Step 4: Embryo Culture and Biopsy
Fertilized eggs are cultured in the laboratory to the blastocyst stage (day 5-6). An embryologist removes 3-5 cells from the trophectoderm for genetic testing, while the embryo itself remains unaffected. After biopsy, all embryos are cryopreserved.
Step 5: Genetic Testing and Screening
The removed cells are sent for analysis using PGT-M/PGT-SR/PGT-A. The testing period is approximately 2 to 4 weeks. The results will clearly indicate whether each embryo carries the pathogenic gene or chromosomal abnormality, providing a judgment of "transferable," "non-transferable," or "borderline/requires review."
Step 6: Frozen Embryo Transfer and Subsequent Confirmation
After selecting healthy embryos, a frozen embryo transfer (FET) is performed during the woman's next menstrual cycle. A pregnancy test is done 12-14 days after transfer. If pregnancy is successful, prenatal diagnosis (amniocentesis) is required in the second trimester (around 18 weeks) to verify the embryo genetic test results before continuing the pregnancy.
| Step | Content | Time Required |
|---|---|---|
| ① Genetic Counseling & Family Verification | Confirm genetic disease type, collect proband sample | 1-2 weeks |
| ② Genetic Testing & Probe Design | Customize PGT-M detection probes | 1-3 months |
| ③ Ovarian Stimulation & Egg Retrieval | Medication for stimulation, ultrasound monitoring, egg retrieval surgery | 2-3 weeks |
| ④ IVF & Blastocyst Culture | ICSI fertilization, culture to blastocyst stage | 5-6 days |
| ⑤ Embryo Biopsy & Genetic Testing | Trophectoderm cell sampling, PGT analysis | 2-4 weeks |
| ⑥ Frozen Embryo Transfer | Transfer of screened healthy embryos | 1 cycle |
| ⑦ Prenatal Diagnosis Confirmation | Amniocentesis verification | Around 18 weeks of pregnancy |
Doctor's Perspective: Genetic Counseling is the Cornerstone of PGT
In the reproductive genetics clinic, the doctor's first task is to determine: Is this genetic disease suitable for PGT? Not all genetic diseases are appropriate for third-generation IVF.
- Suitable cases: Monogenic genetic diseases with a clear pathogenic gene (e.g., α-thalassemia, β-thalassemia, SMA, hereditary deafness GJB2 gene mutation); chromosomal structural abnormalities (balanced translocation, Robertsonian translocation); some mitochondrial genetic diseases (requires assessment of mutation load).
- Unsuitable or cautious cases: Polygenic genetic diseases (e.g., certain types of diabetes, hypertension, schizophrenia, where current technology cannot accurately assess embryo risk); de novo mutations where pathogenicity cannot be confirmed; diseases with high genetic heterogeneity (multiple genes can cause the same phenotype); mitochondrial diseases where mutation load is below threshold may not be completely blocked.
Clinical Point During the initial genetic counseling, the doctor will order tests such as complete blood count, hemoglobin electrophoresis, and gene sequencing to confirm the diagnosis and pathogenic site. If both partners are carriers of the same recessive genetic disease (e.g., both are thalassemia carriers), the indication for PGT-M is very clear.
Five Most Easily Overlooked Details
- Probe design requires a proband sample. If no one in the family is affected, or if the proband has passed away without a DNA sample, probe design may not be possible. In such cases, linkage analysis using embryos can be considered, but accuracy will be lower.
- PGT cannot detect de novo mutations. If the genetic disease is caused by a new mutation occurring in the embryo itself, with both parents having normal genes, PGT cannot predict it. It can only be investigated through prenatal diagnosis.
- Not all embryos will pass testing. For autosomal dominant diseases, theoretically 50% of embryos carry the pathogenic gene; for recessive diseases, 25% are affected, 50% are carriers. The actual proportion of usable embryos may be lower, and some cycles may result in no embryos available for transfer.
- Prenatal diagnosis is not optional. PGT is an embryo-level screening with a 1% to 2% risk of misdiagnosis or missed diagnosis. Therefore, amniocentesis in the second trimester is mandatory for verification.
- PGT-A and PGT-M cannot replace each other. PGT-A only checks chromosome number, not single-gene diseases; PGT-M only checks specific genes, not chromosomes. They can be used together, but the cost and testing time will increase accordingly.
Management Strategies for Special Genetic Conditions
| Genetic Disease Type | PGT Feasibility | Special Considerations |
|---|---|---|
| Autosomal Dominant (e.g., Marfan syndrome, Huntington's disease) | Feasible (PGT-M) | Need to identify which parent carries the mutation; some diseases have incomplete penetrance, requiring family analysis |
| Autosomal Recessive (e.g., thalassemia, SMA) | Feasible (PGT-M) | Both carriers → 25% affected embryos, 50% carriers, 25% normal; transfer of carrier embryos requires ethical evaluation |
| X-linked Recessive (e.g., hemophilia, DMD) | Feasible (PGT-M) | 50% of male embryos affected, 50% of female embryos carriers; sex selection can be performed simultaneously |
| Chromosomal Balanced Translocation | Feasible (PGT-SR) | Probability of normal/balanced embryos from a translocation carrier is about 10%-30%, depending on the translocation type |
| Mitochondrial Genetic Disease | Partially feasible | Requires assessment of mutation load threshold; embryos with low load may be transferable, but uncertainty exists |
| Polygenic Genetic Disease | Currently not applicable | Technology is still in the research phase and not routinely used clinically |
Time Planning: How Long from Initial Consultation to Transfer
The overall timeline can be divided into three phases:
- Preparation Phase (1-3 months): Genetic counseling, family verification, genetic testing, probe design. For common mutations (e.g., common thalassemia deletions in the Chinese population), probe design may be faster; rare mutations or diseases requiring custom probes may take longer.
- Treatment Phase (1-2 months): Ovarian stimulation, egg retrieval, IVF, blastocyst culture, biopsy, genetic testing. Genetic testing results take 2-4 weeks.
- Transfer Phase (1 month): Frozen embryo transfer, pregnancy test. If the first transfer is unsuccessful, remaining embryos can be used for a second transfer.
Overall, a complete PGT cycle from initial consultation to confirmed pregnancy typically takes 4 to 6 months. If probe design goes smoothly and ovarian response is good, it can be completed in as little as 3 months.
Frequently Asked Questions About IVF for Genetic Diseases
No, it cannot guarantee 100%. The accuracy of PGT is about 98% to 99%, with a very low risk of misdiagnosis or missed diagnosis due to mosaicism. Therefore, all PGT pregnancies require prenatal diagnosis (amniocentesis) in the second trimester for confirmation. Additionally, PGT only tests for known pathogenic genes and cannot rule out the possibility of new mutations occurring during embryo development.
Currently, mainstream reproductive centers in China perform biopsy at the blastocyst stage (day 5-6) by taking trophectoderm cells. At this stage, the embryo has differentiated into the inner cell mass (which will develop into the fetus) and the trophectoderm (which will develop into the placenta). Biopsy only takes trophectoderm cells and has no significant impact on the embryo's developmental potential. Multiple studies show no significant difference in implantation and live birth rates between PGT-tested embryos and non-biopsied embryos.
In China, the cost of one PGT cycle varies by region, hospital, and type of genetic disease. It typically includes: genetic testing and probe design fees (10,000-30,000 RMB), IVF cycle fees (30,000-50,000 RMB), and embryo genetic testing fees (20,000-40,000 RMB, depending on the number of embryos). The total cost is generally between 60,000 and 120,000 RMB. Costs may be higher in first-tier cities or leading reproductive centers. PGT costs are currently not covered by medical insurance and must be paid out-of-pocket.
As of 2025, among the medical institutions approved to provide assisted reproductive technology in China, approximately 100 have PGT qualifications (including PGT-M/PGT-SR/PGT-A). These hospitals are mainly located in provincial capitals and tertiary hospital reproductive centers. It is recommended to choose centers with a high annual number of PGT cycles and specialized genetic counseling clinics for more experienced care.
Probe design failure or inability to customize probes can occur, for example: no proband in the family, mutation type is a duplication/deletion that cannot be designed for, or the pathogenic gene is not yet identified. In such cases, the doctor may suggest: ① Using linkage analysis as an alternative (slightly lower accuracy); ② Using donor embryos; ③ Considering natural pregnancy with prenatal diagnosis. The specific approach depends on the family's individual situation.
Practitioner's Observation: Common Cognitive Biases in Clinical Practice
In the genetic counseling clinic, several situations recur that families preparing for PGT should be aware of:
- The misconception that "PGT guarantees everything": PGT is a screening tool, not a treatment. It cannot repair genetic defects in embryos; it only screens for known specific genes. For certain genetic syndromes (e.g., Noonan syndrome, Neurofibromatosis) involving multiple genes or somatic mosaicism, the applicability of PGT is limited.
- The wrong order of "doing IVF first, then testing": The correct process is to first undergo genetic counseling and genetic testing, confirm the pathogenic site, and complete probe design before entering the IVF cycle. Doing IVF first and waiting for probes may result in prolonged embryo freezing or probe incompatibility.
- The misunderstanding that "genetic diseases require third-generation IVF": For some genetic diseases (e.g., certain autosomal recessive diseases), if both partners are only carriers, they can choose natural pregnancy with prenatal diagnosis instead of PGT. PGT is suitable for families with a clear risk of genetic disease who wish to minimize the chance of transmission.
- Neglecting the importance of psychological support: During a PGT cycle, situations such as no embryos available for transfer, unsatisfactory test results, or failed transfer can cause significant psychological stress. It is advisable to check if the reproductive center offers psychological counseling resources.
▎Doctor's Advice
If you or your partner is diagnosed as a patient or carrier of a genetic disease and plans to use IVF technology to block its transmission, here are some steps you can start preparing now:
- Compile complete family genetic history records, including the proband's diagnosis certificate and genetic test report (if available).
- Both partners should visit a reproductive center with genetic counseling qualifications for an initial evaluation to determine the suitability and feasibility of PGT.
- Plan your time: From genetic counseling to embryo transfer generally takes 4-6 months, and the probe design phase requires patience.
- Understand the limitations of PGT: It cannot test for all genetic diseases, cannot replace prenatal diagnosis, and carries a certain risk of failure.
- Choose a qualified reproductive center with PGT accreditation and avoid being misled by advertisements from unregulated institutions.
Blocking genetic diseases is a rigorous medical process requiring collaboration among geneticists, reproductive doctors, embryologists, and the patient's family. Scientific evaluation, rational decision-making, and thorough preparation are the foundations for achieving good outcomes.
⚠ Risk Reminder
PGT technology cannot cover all types of genetic diseases. De novo mutations, polygenic genetic diseases, some mitochondrial genetic diseases, and diseases with unidentified pathogenic genes may not be blockable using current technology. All PGT pregnancies require final confirmation through prenatal diagnosis (amniocentesis). Each family's genetic background is different, so specific plans should be based on genetic counseling and clinical evaluation at a qualified reproductive center.
Assisted Reproduction Knowledge Base · Patient Education Content · Non-Promotional
Comments (0)